[HTML][HTML] Neuroprotective agents in the management of glaucoma
Glaucoma is an optic neuropathy, specifically a neurodegenerative disease characterized
by loss of retinal ganglion cells (RGCs) and their axons. The pathogenesis of RGC loss in …
by loss of retinal ganglion cells (RGCs) and their axons. The pathogenesis of RGC loss in …
Neuroprotection in glaucoma: drug-based approaches
W Cheung, L Guo, MF Cordeiro - Optometry and Vision Science, 2008 - journals.lww.com
In recent years the focus of glaucoma research has shifted toward neuroprotection, as the
traditional strategies of lowering intraocular pressure have been shown to be unable to …
traditional strategies of lowering intraocular pressure have been shown to be unable to …
Beyond intraocular pressure: neuroprotective strategies for future glaucoma therapy
ATE Hartwick - Optometry and vision science, 2001 - journals.lww.com
Background. All currently approved glaucoma medications are directed toward lowering
intraocular pressure. However, it is apparent that there are pressure-independent …
intraocular pressure. However, it is apparent that there are pressure-independent …
[PDF][PDF] Disease progression and the need for neuroprotection in glaucoma management
R Varma, P Peeples, JG Walt… - Am J Manag …, 2008 - ajmc.s3.amazonaws.com
Glaucoma, the second leading cause of worldwide blindness, is a progressive optic
neuropathy characterized by a loss of retinal ganglion cells and their axons beyond typical …
neuropathy characterized by a loss of retinal ganglion cells and their axons beyond typical …
Changing therapeutic paradigms in glaucoma management
R David - Expert opinion on investigational drugs, 1998 - Taylor & Francis
Glaucoma is a family of diseases commonly characterised by progressive optic neuropathy
with associated visual field deficits for which elevated intraocular pressure (IOP) is one of the …
with associated visual field deficits for which elevated intraocular pressure (IOP) is one of the …
[HTML][HTML] Suppl 1: M5: Present and new treatment strategies in the management of glaucoma
M Kolko - The open ophthalmology journal, 2015 - ncbi.nlm.nih.gov
Glaucoma is a neurodegenerative disease characterized by retinal ganglion cell (RGC)
death and axonal loss. It remains a major cause of blindness worldwide. All current …
death and axonal loss. It remains a major cause of blindness worldwide. All current …
[HTML][HTML] Neuroprotection in glaucoma
SK Vasudevan, V Gupta… - Indian journal of …, 2011 - journals.lww.com
Glaucoma is a neurodegenerative disease characterized by loss of retinal ganglion cells
and their axons. Recent evidence suggests that intraocular pressure (IOP) is only one of the …
and their axons. Recent evidence suggests that intraocular pressure (IOP) is only one of the …
Glaucoma neuroprotection: What is it? Why is it needed?
RN Weinreb - Canadian journal of ophthalmology, 2007 - Elsevier
Glaucoma neuroprotection: What is it? Why is it needed? Page 1 396 Glaucoma
neuroprotection—Weinreb Glaucoma neuroprotection: What is it? Why is it needed? Robert …
neuroprotection—Weinreb Glaucoma neuroprotection: What is it? Why is it needed? Robert …
Neuroprotective therapies for glaucoma
W Song, P Huang, C Zhang - Drug design, development and …, 2015 - Taylor & Francis
Glaucoma is the second leading cause for blindness worldwide. It is mainly caused by
glaucomatous optic neuropathy (GON) characterized by retinal ganglion cell loss, which …
glaucomatous optic neuropathy (GON) characterized by retinal ganglion cell loss, which …